OGN trades 5.4% above Wall Street's consensus target of $13.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes OGN achieves its forward estimates and maintains a stable P/E multiple of 4.1x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 7, 2026, Organon & Co. (OGN) has a Wall Street consensus price target of $13.00, based on estimates from 9 covering analysts. With the stock currently trading at $13.74, this represents a potential downside of -5.4%. The company has a market capitalization of $3.61B.
Analyst price targets range from a low of $12.00 to a high of $14.00, representing a 15% spread in expectations. The median target of $13.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 3 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, OGN trades at a trailing P/E of 19.1x and forward P/E of 4.1x. Analysts expect EPS to grow +333.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $40.32, with bear and bull scenarios of $25.40 and $53.13 respectively. Model confidence stands at 38/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PFEPfizer Inc. | $156.6B | $27.48 | $28.50 | +3.7% | Hold | 9.2x | 39 |
 VTRSViatris Inc. | $20.4B | $17.54 | $21.40 | +22.0% | Hold | 7.0x | 13 |
 ABBVAbbVie Inc. | $471.4B | $266.79 | $287.08 | +7.6% | Buy | 19.0x | 43 |
 HLNHaleon plc | $39.6B | $8.87 | $10.20 | +15.0% | Buy | 21.0x | 4 |
 TEVATeva Pharmaceutical Industries Limited | $46.2B | $39.13 | $45.80 | +17.0% | Buy | 19.8x | 46 |
 PRGOPerrigo Company plc | $1.9B | $14.00 | $36.20 | +158.6% | Hold | 6.4x | 36 |
 EVAXEvaxion Biotech A/S | $20M | $3.16 | — | — | — | — | — |
 ANIPANI Pharmaceuticals, Inc. | $1.6B | $71.52 | $99.50 | +39.1% | Buy | 7.7x | 10 |
 MCKMcKesson Corporation | $109.9B | $921.67 | $953.00 | +3.4% | Buy | 20.6x | 31 |
 CAHCardinal Health, Inc. | $54.7B | $233.44 | $273.22 | +17.0% | Buy | 18.6x | 33 |
Quick answers to the most common questions about buying OGN stock.
Wall Street's consensus price target for OGN is $13, -5.4% from its current price of $13.74. The below-market target from 9 analysts suggests limited near-term appreciation.
OGN has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is leaning bearish, with 3 Sell/Strong Sell ratings. The consensus 12-month price target of $13 implies -5.4% downside from current levels.
With a forward P/E of 4.1015x, OGN trades at a relatively low valuation. The consensus target of $13 implies -5.4% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $14 for OGN, while the most conservative target is $12. The consensus of $13 represents the median expectation. Our quantitative valuation model projects a bull case target of $53 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
OGN is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 4 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month OGN stock forecast based on 9 Wall Street analysts shows a consensus price target of $13, with estimates ranging from $12 (bear case) to $14 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $40, with bear/bull scenarios of $25/$53.
Our quantitative valuation model calculates OGN's fair value at $40 (base case), with a bear case of $25 and bull case of $53. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 38/100.
OGN trades at a forward P/E ratio of 4.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on OGN, with 3 Sell ratings and a price target of $13 (-5.4% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
OGN analyst price targets range from $12 to $14, a 15% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13 consensus represents the middle ground. Our model's $25-$53 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.